1. Synthesis and evaluation of 1,2,3,4-tetrahydro-1-acridone analogues as potential dual inhibitors for amyloid-beta and tau aggregation
- Author
-
Peng Lv, Shi-Liang Huang, Zhen-Quan Liu, Ning Wang, Zhi-Shu Huang, and Chun-Li Xia
- Subjects
0301 basic medicine ,Swine ,Amyloid beta ,Clinical Biochemistry ,Tau protein ,Pharmaceutical Science ,tau Proteins ,Protein aggregation ,Blood–brain barrier ,01 natural sciences ,Biochemistry ,Protein Aggregates ,Structure-Activity Relationship ,03 medical and health sciences ,chemistry.chemical_compound ,Microscopy, Electron, Transmission ,Drug Discovery ,medicine ,Animals ,Humans ,Structure–activity relationship ,Molecular Biology ,Amyloid beta-Peptides ,Microscopy, Confocal ,biology ,010405 organic chemistry ,Chemistry ,Organic Chemistry ,Surface Plasmon Resonance ,Peptide Fragments ,In vitro ,0104 chemical sciences ,Acridone ,HEK293 Cells ,030104 developmental biology ,medicine.anatomical_structure ,Blood-Brain Barrier ,Drug Design ,Tacrine ,biology.protein ,Molecular Medicine ,Acridones ,Central Nervous System Agents ,medicine.drug - Abstract
Amyloid-β (Aβ) and tau protein are two crucial hallmarks in Alzheimer's disease (AD). Their aggregation forms are thought to be toxic to the neurons in the brain. A series of new 1,2,3,4-tetrahydro-1-acridone analogues were designed, synthesized, and evaluated as potential dual inhibitors for Aβ and tau aggregation. In vitro studies showed that compounds 25-30 (20 μM) with N-methylation of the quinolone ring effectively inhibited Aβ1-42 aggregation by 84.7%-99.5% and tau aggregation by 71.2%-101.8%. Their structure-activity relationships are discussed. In particular, 30 could permeate the blood-brain barrier, bind to Aβ1-42 and tau, inhibit Aβ1-42 β-sheets formation, and prevent tau aggregation in living cells.
- Published
- 2018